cholecystokinin-(26-33) has been researched along with Diabetes-Mellitus--Type-1* in 1 studies
1 other study(ies) available for cholecystokinin-(26-33) and Diabetes-Mellitus--Type-1
Article | Year |
---|---|
[Effect of conjunctive instillation of cholecystokinin 26-33 on pancreatic endocrine function in type 1 diabetes mellitus].
To investigate the role of cholecystokinin (ChCK) in the pathogenesis of insulin-dependent diabetes mellitus (IDDM) and to search the ways of its treatment with good prospects we conducted a comparative study of the effects of chronic conjunctive instillations (c.i.)) and intracerebroventricular administrations (i.c.v.) of cholecystokinin octapeptide (ChCK-8) to intact and streptozotocin-induced IDDM rats. The state of alpha- and beta-cells in pancreatic islets was studied by immunocytochemical method with a subsequent quantitative analysis on an automatic image analysis system. Our investigation has shown that in healthy rats both i.c.v. and c.i. administrations of ChCK-8 induced a significant increase in glycemia due to stimulation of alpha-cells and depression of beta-cells. However effects of ChCK-8 on the synthesis and secretion of insulin prevailed at i.c.v. administrations, while ChCK-8 administrated by c.i. was more potent in stimulating alpha-cells. Both ways of ChCK-8 administrations to a IDDM rats caused a positive effect on those animals by inhibiting a destruction of beta-cells, stimulating their function, and decreasing the content of alpha-cells in pancreatic islets which lead to a significant increase in insulin and a decrease in glucose in blood. Topics: Animals; Conjunctiva; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Injections, Intraventricular; Instillation, Drug; Insulin; Islets of Langerhans; Male; Rats; Rats, Wistar; Sincalide | 2003 |